Decade of Worldwide Life-Saving Experience—Now in the U.S.
Curosurf is indicated for the treatment (rescue) of Respiratory Distress Syndrome (RDS) in premature infants. Curosurf compensates for the deficiency of surfactant in preterm infants with RDS and restores surface activity to the lungs of these infants.
Since its introduction in Europe in 1992, Curosurf has been used to treat more than 300,000 infants.
Curosurf is the #1 selling surfactant in Europe, with approximately 70% of market share.
Curosurf is available in 43 countries worldwide.
More than 800 bibliographic references are cited in the literature.
Now in the United States
Curosurf is available in the United States exclusively from DEY.
Curosurf was approved by the FDA based on the results of two multi-center, randomized and controlled European studies conducted by Chiesi Farmaceutici S.p.A.
Curosurf proved safe and effective in compensating for deficiencies of naturally occurring pulmonary surfactant.
Curosurf is the only porcine-derived surfactant in the U.S.
Lowest Volume, Long Dosing Interval, Fast Action
Lowest-Volume Surfactant for RDS
Curosurf is the most concentrated surfactant available in the United States.
Unlike other surfactants, repeat doses of Curosurf are only 50% of the initial dose.
The result: Less volume of Curosurf is required for initial and repeat dosing than with Infasurf and Survanta®.
The result: Less time devoted to administering surfactant therapy leaves more time for other critical tasks in neonatal care.
Rapid Onset of Action
Curosurf rapidly improves oxygenation.
In three randomized clinical trials, marked improvement in oxygenation has been seen within 5 minutes. 2,3,4.
The result: Curosurf reduces exposure to supplemental oxygen and helps restore normal lung function.
Clinical studies have not evaluated if low volume results in superior safety or efficacy on clinically relevant endpoints
Physiological endpoints have not proven to impact key clinical outcomes such as mortality due to RDS
Curosurf is available in two vial sizes: 1.5 mL (120 mg phospholipids and 1.5 mg protein) and 3 mL (240 mg phospholipids and 3 mg protein).
Cautions: Curosurf should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants. Infants receiving Curosurf should receive frequent clinical and laboratory assessments so that oxygen and ventilator support can be modified to respond to respiratory changes. Transient adverse effects seen with the administration of Curosurf include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation.
SURVANTA is a registered trademark of Ross Product Division, Abbott Laboratories Inc.
